Cargando…

Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study

The acute diarrhea is a wide-spread disease. The prescription of enterosorbents is appropriate as a primary measure for the treatment of the acute diarrhea for effective prevention of the fluid and electrolyte loss, as well as method for symptom relief of the attack of the disease. Aim of the study...

Descripción completa

Detalles Bibliográficos
Autores principales: Tieroshyn, Vadim, Moroz, Larisa, Prishliak, Oleksandra, Shostakovich-Koretska, Lyudmila, Kruglova, Oksana, Gordienko, Lyudmila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156649/
https://www.ncbi.nlm.nih.gov/pubmed/32286322
http://dx.doi.org/10.1038/s41598-020-62386-0
_version_ 1783522255770222592
author Tieroshyn, Vadim
Moroz, Larisa
Prishliak, Oleksandra
Shostakovich-Koretska, Lyudmila
Kruglova, Oksana
Gordienko, Lyudmila
author_facet Tieroshyn, Vadim
Moroz, Larisa
Prishliak, Oleksandra
Shostakovich-Koretska, Lyudmila
Kruglova, Oksana
Gordienko, Lyudmila
author_sort Tieroshyn, Vadim
collection PubMed
description The acute diarrhea is a wide-spread disease. The prescription of enterosorbents is appropriate as a primary measure for the treatment of the acute diarrhea for effective prevention of the fluid and electrolyte loss, as well as method for symptom relief of the attack of the disease. Aim of the study - the antidiarrheal efficacy and safety study of high-dispersion silicon dioxide enterosorbent in tablet dosage form in patients with acute diarrhea. This was randomized, double-blind, placebo-controlled, 4-center study. Acute diarrhea was defined as three and more episodes of watery stool per day either during 48 hours or less before study entry in the patients having normal stool recently. It has been postulated that symptoms and signs of acute diarrhea have to be caused by direct infection of the gastrointestinal tract and did not associated with moderate-to-severe systemic states. 144 patients with established acute diarrhea were randomized into treatment group (enterosorbent “Carbowhite”, n = 120) or placebo group. Date collection including severity diarrhea, systemic symptoms was performed at baseline and daily during 7 days. Stool examination and serological assay were performed at baseline. The primary end points were declared as time to complete recovery from acute diarrhea. It has been found that the use of the siliceous enterosorbent (“Carbowhite”) allowed to reduce (p < 0.001) the treatment period averagely for 0.9 days (95% confidence interval 0.5–1.2 days) in comparison with placebo. Data of safety monitoring has revealed that both patient groups had negative stool culture, while initiation of antibiotic treatment was run more frequently in placebo group (8.3%) compared to investigational product group (4.1%, P = 0.044). The siliceous enterosorbent “Carbowhite” was well tolerated and reduced the recovery time of the acute episode of the diarrhea in the clinically significant form.
format Online
Article
Text
id pubmed-7156649
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71566492020-04-19 Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Tieroshyn, Vadim Moroz, Larisa Prishliak, Oleksandra Shostakovich-Koretska, Lyudmila Kruglova, Oksana Gordienko, Lyudmila Sci Rep Article The acute diarrhea is a wide-spread disease. The prescription of enterosorbents is appropriate as a primary measure for the treatment of the acute diarrhea for effective prevention of the fluid and electrolyte loss, as well as method for symptom relief of the attack of the disease. Aim of the study - the antidiarrheal efficacy and safety study of high-dispersion silicon dioxide enterosorbent in tablet dosage form in patients with acute diarrhea. This was randomized, double-blind, placebo-controlled, 4-center study. Acute diarrhea was defined as three and more episodes of watery stool per day either during 48 hours or less before study entry in the patients having normal stool recently. It has been postulated that symptoms and signs of acute diarrhea have to be caused by direct infection of the gastrointestinal tract and did not associated with moderate-to-severe systemic states. 144 patients with established acute diarrhea were randomized into treatment group (enterosorbent “Carbowhite”, n = 120) or placebo group. Date collection including severity diarrhea, systemic symptoms was performed at baseline and daily during 7 days. Stool examination and serological assay were performed at baseline. The primary end points were declared as time to complete recovery from acute diarrhea. It has been found that the use of the siliceous enterosorbent (“Carbowhite”) allowed to reduce (p < 0.001) the treatment period averagely for 0.9 days (95% confidence interval 0.5–1.2 days) in comparison with placebo. Data of safety monitoring has revealed that both patient groups had negative stool culture, while initiation of antibiotic treatment was run more frequently in placebo group (8.3%) compared to investigational product group (4.1%, P = 0.044). The siliceous enterosorbent “Carbowhite” was well tolerated and reduced the recovery time of the acute episode of the diarrhea in the clinically significant form. Nature Publishing Group UK 2020-04-14 /pmc/articles/PMC7156649/ /pubmed/32286322 http://dx.doi.org/10.1038/s41598-020-62386-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Tieroshyn, Vadim
Moroz, Larisa
Prishliak, Oleksandra
Shostakovich-Koretska, Lyudmila
Kruglova, Oksana
Gordienko, Lyudmila
Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
title Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
title_full Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
title_fullStr Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
title_full_unstemmed Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
title_short Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
title_sort colloidal silicon dioxide in tablet form (carbowhite) efficacy in patients with acute diarrhea: results of randomized, double-blind, placebo-controlled, multi-center study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156649/
https://www.ncbi.nlm.nih.gov/pubmed/32286322
http://dx.doi.org/10.1038/s41598-020-62386-0
work_keys_str_mv AT tieroshynvadim colloidalsilicondioxideintabletformcarbowhiteefficacyinpatientswithacutediarrhearesultsofrandomizeddoubleblindplacebocontrolledmulticenterstudy
AT morozlarisa colloidalsilicondioxideintabletformcarbowhiteefficacyinpatientswithacutediarrhearesultsofrandomizeddoubleblindplacebocontrolledmulticenterstudy
AT prishliakoleksandra colloidalsilicondioxideintabletformcarbowhiteefficacyinpatientswithacutediarrhearesultsofrandomizeddoubleblindplacebocontrolledmulticenterstudy
AT shostakovichkoretskalyudmila colloidalsilicondioxideintabletformcarbowhiteefficacyinpatientswithacutediarrhearesultsofrandomizeddoubleblindplacebocontrolledmulticenterstudy
AT kruglovaoksana colloidalsilicondioxideintabletformcarbowhiteefficacyinpatientswithacutediarrhearesultsofrandomizeddoubleblindplacebocontrolledmulticenterstudy
AT gordienkolyudmila colloidalsilicondioxideintabletformcarbowhiteefficacyinpatientswithacutediarrhearesultsofrandomizeddoubleblindplacebocontrolledmulticenterstudy